Sustained reductions in hyperglycemia using a diabetes app with connected glucose meters in people with type 2 diabetes at higher risk for complications

Aim: Assess the benefits of using a diabetes app and connected blood glucose (BG) meter in people with type 2 diabetes (PwT2D) with higher-than-recommended mean BG. It is well understood that sustained higher levels of glycemia are linked to diabetes related complications and that early intervention to reduce hyperglycemia is an important clinical goal. Methods: We sourced server data from a total population of 22,696 PwT2D using the OneTouch Reveal diabetes app in conjunction with a OneTouch Verio Flex or Reflect BG meter. We identified three groups (mean BG > 180, > 155, and between > 155 and < 180 mg/dL) at higher risk for diabetes-associated complications based on their hyperglycemia. Data from their first 14 days using the app was compared with the last 14 days at the end of each timeframe, using paired within-subject differences. Results: At 1 year in PwT2D with baseline mean BG > 155 mg/dL, readings in range (RIR) improved by 24.0%, and mean BG decreased by 35.9 mg/dL, from 196.4 mg/dL to 160.5 mg/dL. These improvements were due to reductions in hyperglycemic readings. Subjects with the highest baseline mean BG of > 180 mg/dL had the greatest reduction (–54.3 mg/dL) in mean BG after experiencing the new app and meter for 1 year. Those engaging more often with the app had greater improvements in glycemia. Conclusions: In PwT2D with higher-than-recommended mean BG, substantial improvements in glycemia were associated with subjects using a diabetes app with a connected blood glucose meter at 3 months, and these improvements were sustained out to 1-year.

Authors

Institutions

Publication Details

Journal
Exploration of Endocrine and Metabolic Diseases
Published
2026-07-16
DOI
https://doi.org/10.37349/eemd.2026.101478
Primary Topic
Mobile Health and mHealth Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sustained reductions in hyperglycemia using a diabetes app with connected glucose meters in people with type 2 diabetes at higher risk for complications

Mike Grady, Elizabeth H. Holt, Matthew Fryett, Stephen Mackintosh
Exploration of Endocrine and Metabolic Diseases
Mobile Health and mHealth Applications
article

Sustained reductions in hyperglycemia using a diabetes app with connected glucose meters in people with type 2 diabetes at higher risk for complications

Mike Grady, Elizabeth H. Holt, Matthew Fryett, Stephen Mackintosh
article en

Abstract

Aim: Assess the benefits of using a diabetes app and connected blood glucose (BG) meter in people with type 2 diabetes (PwT2D) with higher-than-recommended mean BG. It is well understood that sustained higher levels of glycemia are linked to diabetes related complications and that early intervention to reduce hyperglycemia is an important clinical goal. Methods: We sourced server data from a total population of 22,696 PwT2D using the OneTouch Reveal diabetes app in conjunction with a OneTouch Verio Flex or Reflect BG meter. We identified three groups (mean BG > 180, > 155, and between > 155 and < 180 mg/dL) at higher risk for diabetes-associated complications based on their hyperglycemia. Data from their first 14 days using the app was compared with the last 14 days at the end of each timeframe, using paired within-subject differences. Results: At 1 year in PwT2D with baseline mean BG > 155 mg/dL, readings in range (RIR) improved by 24.0%, and mean BG decreased by 35.9 mg/dL, from 196.4 mg/dL to 160.5 mg/dL. These improvements were due to reductions in hyperglycemic readings. Subjects with the highest baseline mean BG of > 180 mg/dL had the greatest reduction (–54.3 mg/dL) in mean BG after experiencing the new app and meter for 1 year. Those engaging more often with the app had greater improvements in glycemia. Conclusions: In PwT2D with higher-than-recommended mean BG, substantial improvements in glycemia were associated with subjects using a diabetes app with a connected blood glucose meter at 3 months, and these improvements were sustained out to 1-year.

Exploration of Endocrine and Metabolic DiseasesVol. 3
NovaBiotics (United Kingdom) (GB), LifeSensors (United States) (US)
Quality Education
Openalex Percentile: Top 5%
Mobile Health and mHealth Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.